Corvus Pharmaceuticals (NASDAQ:CRVS) Coverage Initiated by Analysts at HC Wainwright

Analysts at HC Wainwright started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) in a note issued to investors on Thursday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $11.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 105.61% from the company’s current price.

Several other equities analysts also recently weighed in on CRVS. StockNews.com downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Mizuho raised shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. LADENBURG THALM/SH SH raised their target price on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a report on Monday, September 16th. Finally, Oppenheimer raised their price objective on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Corvus Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $12.38.

Corvus Pharmaceuticals Trading Up 1.9 %

CRVS stock opened at $5.35 on Thursday. Corvus Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $10.00. The company has a market cap of $343.77 million, a P/E ratio of -5.75 and a beta of 1.05. The company’s 50-day moving average price is $7.77 and its 200 day moving average price is $5.26.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CRVS. Nwam LLC purchased a new position in shares of Corvus Pharmaceuticals during the 3rd quarter worth about $53,000. XTX Topco Ltd purchased a new position in shares of Corvus Pharmaceuticals in the 3rd quarter worth $74,000. Virtu Financial LLC acquired a new position in Corvus Pharmaceuticals in the third quarter valued at $83,000. Oppenheimer & Co. Inc. purchased a new stake in Corvus Pharmaceuticals during the third quarter valued at about $89,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Corvus Pharmaceuticals in the second quarter valued at approximately $44,000. 46.64% of the stock is currently owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.